Podchaser Logo
Home
Cagri Savran - One Cell in a Billion - Better liquid biopsies of breast cancer and non-invasive prenatal tests are on the horizon

Cagri Savran - One Cell in a Billion - Better liquid biopsies of breast cancer and non-invasive prenatal tests are on the horizon

Released Wednesday, 27th October 2021
Good episode? Give it some love!
Cagri Savran - One Cell in a Billion - Better liquid biopsies of breast cancer and non-invasive prenatal tests are on the horizon

Cagri Savran - One Cell in a Billion - Better liquid biopsies of breast cancer and non-invasive prenatal tests are on the horizon

Cagri Savran - One Cell in a Billion - Better liquid biopsies of breast cancer and non-invasive prenatal tests are on the horizon

Cagri Savran - One Cell in a Billion - Better liquid biopsies of breast cancer and non-invasive prenatal tests are on the horizon

Wednesday, 27th October 2021
Good episode? Give it some love!
Rate Episode

Sal's Investment Syndicate: Click to Join

Sponsored by:

  • Purdue University entrepreneurship
  • Peter Fasse, patent attorney at Fish & Richardson

I invested in Savran Tech back in 2017 around the time of the first part of this interview. Recently I sat down with Cagri Savran to review the progress of his remarkable biotech startup in the last four years. Listen to the original interview followed by a recent update.

Here is a list of the topics discussed:

  • Çağrı Savran Bio (Çağrı Is Pronounced Cha-re)
  • Accident that Took Çağrı Savran from Turkey to Indiana
  • Purdue University’s Remarkable Support for the Commercialization of Faculty Inventions
  • Çağrı Savran: “So, when I say "extremely rare," I mean one-in-a-billion rare.”
  • Çağrı Savran: “Our technology can find those five or six or ten cells that are, among about a billion.“
  • “…from a blood sample, you have a glimpse into the tumor without cutting into the person.”
  • The Promise of Monitoring Cancer Treatment with a Blood Draw
  • “The advantage is if you can do this with a blood sample, it gives you a chance to do this test frequently, right?”
  • Applicable to the Prenatal Monitoring of the Fetus
  • Savran’s Tech Is Simple, Fast and Results in High Purity and Yield – 1000 Times Faster than Typical Microfluidic Systems
  • Like Alexander with the Gordian Knot, Savran Has Loosened One Constraint to Great Effect
  • Bigger Scale and Faster Flow Allows the Fast Separation of Rare Cells
  • Device Seems Amenable to Large Scale Usage – Handling Many Patients at the Same Time
  • How the Invention Came About
  • Why Çağrı Savran Founded a Company
  • Purdue’s New Commercialization Policy Played a Big Role in the Decision to Found the Company
  • Why Turbocharging Cell Separation Is So Important
  • Other Use Cases: People Are Always Suggesting New Ones but Need to Concentrate
  • Savran’s Tech Is a Game Changer because of Throughput and Parallelization
  • Other Techniques Look at Pieces of DNA – Savran’s Tech Is Capable of Finding the Entire Genome
  • Sal Daher Reads the Review by Spizzy Spong on iTunes and Asks for Your Review
  • How Savran Landed Bigwig Advisor Ken Morse
  • How Savran Found Its CEO – Patrick Rivelli
  • "Oh, you have no idea how I wish that somebody would say that about me, that I'm 'quietly competent.'”
  • Savran’s Choice of the Right Patent Attorney Was Crucial – Peter Fasse Helped Way Beyond Patents
  • Patrick Rivelli, CEO Proposed a New Go to Market Approach
  • What Makes the Savran Lab at Purdue so Productive
  • Çağrı Savran Urges Fellow Academics to Bring Their Inventions to Market
  • Update on the Original Interview with Çağrı Savran, Ph.D.
  • In December of 2017 Savran Was Operating with Essential Components Handmade in the Lab – In October 2021 the Main Components Are Produced by a Vendor
  • Early Technology Was Used in a Major Clinical Trial at Indiana University School of Medicine and Significantly Improved the Ability to Predict Recurrence of a Breast Cancer
  • The Existing Technology for Capturing Circulating Tumor Cells Is Not Scalable – Savran’s Tech Is Amenable to Scale
  • Strategic Players in Prenatal Diagnostics Are Interested in Sequencing the Cells Captured – Savran Is Uniquely Positioned to Provide That Ability
  • The Basic Technology Is Like a Kitchen, the Different Assays Are Like What’s Being Prepared in the Kitchen
  • Savran Has Recruited a Capable and Involved Board
  • Sal Daher Summarizes Savran’s Progress in the Last Four Years
Show More
Rate

Join Podchaser to...

  • Rate podcasts and episodes
  • Follow podcasts and creators
  • Create podcast and episode lists
  • & much more

Episode Tags

Do you host or manage this podcast?
Claim and edit this page to your liking.
,

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features